![Charles Fuchs](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles Fuchs
Hoofd Techniek/Wetenschap/O&O bij
ERASCA, INC.
Vermogen: - $ op 31-07-2026
Profiel
Charles S.
Fuchs is currently Director at the Association of American Cancer Institutes since 2020.
He is also Director at CytomX Therapeutics, Inc. and President-Research & Development at Erasca, Inc., both positions starting in 2026.
Formerly, Dr. Fuchs was Independent Director at CytomX Therapeutics, Inc., Director at Yale Cancer Center from 2017 to 2021, Professor at Harvard Medical School, and Chief Medical Officer at Tubulis GmbH from 2025 to 2026.
Education includes a doctorate from Harvard Medical School conferred in 1986 and a doctorate from Harvard T.H.
Chan School of Public Health conferred in 1994.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 24-07-2026 | 0 ( -.--% ) | - $ | 31-07-2026 |
Actieve functies van Charles Fuchs
| Bedrijven | Functie | Begin |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Directeur/Bestuurslid | 24-07-2026 |
| ERASCA, INC. | Hoofd Techniek/Wetenschap/O&O | 10-08-2026 |
Association of American Cancer Institutes
 Association of American Cancer Institutes Miscellaneous Commercial ServicesCommercial Services Operates as a membership association and cancer research center | Directeur/Bestuurslid | 29-06-2020 |
Eerdere bekende functies van Charles Fuchs
| Bedrijven | Functie | Einde |
|---|---|---|
Tubulis GmbH
 Tubulis GmbH BiotechnologyHealth Technology Develops and manufactures antibody-drug conjugates with biophysical properties to treat cancer tumors | Hoofd Techniek/Wetenschap/O&O | 01-08-2026 |
Yale Cancer Center
 Yale Cancer Center Hospital/Nursing ManagementHealth Services Provides treatment services for cancer patients | Directeur/Bestuurslid | 01-02-2021 |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| CYTOMX THERAPEUTICS, INC. | Directeur/Bestuurslid | - |
Opleiding van Charles Fuchs
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
65
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Yale Cancer Center
Yale Cancer Center Hospital/Nursing ManagementHealth Services Provides treatment services for cancer patients | Health Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Association of American Cancer Institutes
Association of American Cancer Institutes Miscellaneous Commercial ServicesCommercial Services Operates as a membership association and cancer research center | Commercial Services |
Harvard T.H. Chan School of Public Health
 Harvard T.H. Chan School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics, Inc.
 CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Tubulis GmbH
Tubulis GmbH BiotechnologyHealth Technology Develops and manufactures antibody-drug conjugates with biophysical properties to treat cancer tumors | Health Technology |
